Abstracts tagged "Economics"

Abstract Number: 379 • 2013 ACR/ARHP Annual Meeting
Osteoporotic Fracture and Post-Operative Clinical and Cost Outcomes In Rheumatoid Arthritis: Results From Two UK Inception Cohorts
Elena Nikiphorou¹, Lewis Carpenter², Josh Dixey³, Peter Williams⁴, Patrick D. Kiely⁵, David Walsh⁶, Richard Williams⁷ and Adam Young⁸, ¹Research Department of Epidemiology & Public Health, UCL and Rheumatology Department, St Albans City Hospital, ERAS, St Albans City Hospital & University College London (UCL), London, United Kingdom, ²Centre for Lifespan & Chronic Illness Research, University of Hertfordshire, Hatfield, United Kingdom, ³Rheumatology, New Cross Hospital, Wolverhampton, United Kingdom, ⁴Rheumatology, Medway Maritime Hospital, Gillingham, United Kingdom, ⁵Rheumatology Dept, St George's Hospital, London, United Kingdom, ⁶Arthritis Research UK Pain Centre, University of Nottingham, Nottingham, United Kingdom, ⁷Rheumatology, County Hospital, Hereford, United Kingdom, ⁸Rheumatology, ERAS, St Albans City Hospital, St Albans, United Kingdom
Background/Purpose: The risk of osteoporotic fracture is known to be high in RA. Yet less is known about RA related predictive factors for this…
Abstract Number: 717 • 2012 ACR/ARHP Annual Meeting
Results From a Multi-Tiered Item Collection On Linking Systemic Sclerosis to the International Classification of Functioning, Disability and Health: A EULAR Scleroderma Trials and Research Initiative
Lesley Ann Saketkoo¹, Reuben Escorpizo², Kevin J. Keen³, Kim Fligelstone⁴ and Oliver Distler⁵, ¹LSU Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans, LA, ²ICF Research Branch in cooperation with the WHO Collaborating Centre for the Family of International Classifications in Germany (DIMDI), Nottwil, Switzerland, ³Mathematics and Statistics, University of Northern British Columbia, Prince George, BC, Canada, ⁴Royal Free Hospital, Scleroderma Unit and Scleroderma Society, London, United Kingdom, ⁵Department of Rheumatology and Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: Systemic Sclerosis (SSc) affects multiple organs with complex combinations of disability. Skin fibrosis, ischemic pain, ulceration, arthritis, joint contractures, myopathy and cardiopulmonary, renal as…
Abstract Number: 386 • 2012 ACR/ARHP Annual Meeting
Costs of Tumor Necrosis Factor Blockers Per Treated Rheumatoid Arthritis Patient Using Real-World Drug Data in a US Managed Care Population
Vernon F. Schabert¹, Crystal Watson², George Joseph², Paige Iversen¹, Chakkarin Burudpakdee¹ and David J. Harrison², ¹IMS Health, Alexandria, VA, ²Amgen Inc., Thousand Oaks, CA
Background/Purpose: Etanercept (ETN), adalimumab (ADA), and infliximab (INF) are FDA-approved tumor necrosis factor (TNF)-blocker treatments for moderate to severe rheumatoid arthritis (RA) and are commonly…
Abstract Number: 270 • 2012 ACR/ARHP Annual Meeting
Use of Drug Combinations in Patients with Osteoarthritis: A Population-Based Cohort Study
Daniel Prieto-Alhambra¹ and Rosa Morros², ¹Internal Medicine; Primary Care; NDORMS Dept; MRC Lifecourse Epidemiology Unit, URFOA-IMIM, Parc de Salut Mar; Idiap Jordi Gol; University of Oxford; University of Southampton, Barcelona, Spain, ²Primary Care, IDIAP Jordi Gol; Institut Català de la Salut, Spain
TITLE: "Use of drug combinations in patients with osteoarthritis: a population-based cohort study."Background/Purpose: Patients affected with osteoarthritis (OA) use different drugs in search for relief.…
Abstract Number: 60 • 2012 ACR/ARHP Annual Meeting
The Burden of Early Arthritis in Latin America: Utility Analysis Using Patient-Level Data From the Argentinian Consortium for Early Arthritis
Christian A. Waimann¹, Gustavo Citera², Hernan Maldonado Ficco³, Oscar L. Rillo⁴, Mariana Benegas⁵, Rafael Chaparro del Moral⁶, Antonio Catalan Pellet⁷, Anastasia Secco⁸, Lucila Marino⁹, Alberto Berman¹⁰, Horacio Berman¹⁰, Ana Lucía Barbaglia¹¹, Juan Carlos Marcos¹², Josefina Marcos¹³, Francisco Caeiro¹⁴, Maria Haye Salinas¹⁵, Ana C. Alvarez¹⁶, Enrique Soriano¹⁷, Zaida Bedran¹⁸, Sergio Paira¹⁹, Federico Ceccato¹⁹, Gabriela Salvatierra²⁰, Ana Quinteros²¹, Emilio Buschiazzo²² and Edson Javier Velozo²³, ¹Rheumatology section, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ²Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ³Instituto de Rehabilitacion Psicofisica, Buenos Aires, Argentina, ⁴Rheumatology, Hospital General de Agudos "Dr. E. Tornú", Buenos Aires, Argentina, ⁵Rheumatology, Hospital Tornu, Buenos Aires, Argentina, ⁶Rheumatology Section, Hospital General de Agudos Dr. E. Tornú, Buenos Aires, Argentina, ⁷Rheumatology, Hospital Rivadavia, Buenos Aires, Argentina, ⁸Rheumathology, Hospital Bernardino Rivadavia, Buenos aires, Argentina, ⁹Rheumathology, Hospital Bernardino Rivadavia, Buenos Aires, Argentina, ¹⁰Centro Medico Privado de Reumatologia, Tucuman, Argentina, ¹¹Rheumatology, Hospital Padilla, Tucuman, Argentina, ¹²Rheumatology, Hospital San Martin, La Plata, Argentina, ¹³Rheumatology Unit, HIGA San Martín La Plata, La Plata, Argentina, ¹⁴Rheumatology, Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, ¹⁵Reumatología, Hospital Privado de Córdoba, Córdoba, Argentina, ¹⁶Rheumatology, Hospital Privado, Córdoba, Argentina, ¹⁷Rheumatology Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ¹⁸Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ¹⁹Rheumatology, Hospital Jose Maria Cullen, Santa Fe, Argentina, ²⁰Rheumatology, Centro de enfermedades Reumaticas, Santiago Del Estero, Argentina, ²¹Centro Integral de Reumatología, Tucumán, Argentina, ²²Rheumatology, Hospital Señor del Milagro, Salta, Argentina, ²³Rheumatology, Sanatorio Adventista del Plata, Entre Rios, Argentina
Background/Purpose: Rheumatoid arthritis (RA) is estimated to be one of the leading causes of non-fatal burden in the world. However, data from developing countries including…
Abstract Number: 2509 • 2012 ACR/ARHP Annual Meeting
Cost-Effectiveness of Training Rural Providers to Perform Joint Injections
Michael J. Battistone¹, Richard E. Nelson², William D. Ashworth³, Andrea Barker³, Marissa Grotzke⁴, Timothy A. Huhtala⁵, Robert Z. Tashjian⁶ and Grant W. Cannon¹, ¹Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT, ²Division of Epidemiology, Salt Lake City VA and University of Utah, Salt Lake City, UT, ³General Internal Medicine, Salt Lake City VA and University of Utah, Salt Lake City, UT, ⁴Division of Endocrinology, Salt Lake City VA and University of Utah, Salt Lake City, UT, ⁵Division of General Internal Medicine, Salt Lake City VA and University of Utah, Salt Lake City, UT, ⁶Division of Orthopaedics, Salt Lake City VA and University of Utah, Salt Lake City, UT
Background/Purpose: Community based outpatient clinics (CBOCs) have been established by the Department of Veteran Affairs (VA) to provide primary care services to veterans living in…
Abstract Number: 2646 • 2012 ACR/ARHP Annual Meeting
Cost-Effectiveness of Tai Chi Mind-Body Exercise for the Treatment of Fibromyalgia
John B. Wong¹ and Chenchen Wang², ¹Medicine/Clinical Decision Making, Tufts Medical Center, Boston, MA, ²Division of Rheumatology, Tufts Medical Center, Boston, MA
Background/Purpose: Although fibromyalgia is associated with substantial annual direct medical and indirect productivity costs, the cost-effectiveness of treatments for fibromyalgia remains understudied. A randomized…
Abstract Number: 2462 • 2012 ACR/ARHP Annual Meeting
Projecting the Direct Cost Burden of Osteoarthritis in Canada Using a Population-Based Microsimulation Model From [2010-2031]
Behnam Sharif¹, Jacek A. Kopec², Mushfiqur Rahman³, Nick Bansback⁴, Eric C. Sayre², Philippe Finès⁵, Hubert Wong⁶ and Aslam H. Anis⁴, ¹School of Population and Public Health, University of British Columbia, Arthritis Research Centre of Canada, Vancouver, BC, Canada, ²Arthritis Research Centre of Canada, Vancouver, BC, Canada, ³Rheumatology, Arthritis Research Centre of Canada, Vancouver, BC, Canada, ⁴St. Paul's Hospital, Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada, ⁵Statistics Canada, 150 Tunney's Pasture Driveway, Ottawa, ON, Canada, Ottawa, ON, Canada, ⁶School of Population and Public Health, University of British Columbia, St Paul's Hospital, University of British Columbia, Vancouver, V6Z 1Y6, Canada, Vancouver, BC, Canada
Background/Purpose: POHEM-OA (Population Health Model-Osteoarthritis) is a population-based microsimulation model that uses Canadian Community Health Survey-2001 to generate the initial population and models every individual's…
Abstract Number: 1966 • 2012 ACR/ARHP Annual Meeting
Cost-Effectiveness of Bazedoxifene Compared with Raloxifene in the Treatment of Postmenopausal Osteoporotic Women
Mickaël Hiligsmann¹, Wafa Ben Sedrine¹ and J.-Y. Reginster², ¹Department of Public Health, Epidemiology and Health Economics, University of Liege, Liege, Belgium, ²Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium
Background/Purpose: Bazedoxifene is a novel selective estrogen receptor modulator (SERM) in development for the prevention and treatment of osteoporosis. In addition to the therapeutic value…
Abstract Number: 1829 • 2012 ACR/ARHP Annual Meeting
Cost of Etanercept, Adalimumab, and Infliximab in Patients with Rheumatoid Arthritis with Employer Provided Health Insurance
Machaon Bonafede¹, Crystal Watson², George Joseph², Nicole Princic¹ and David J. Harrison², ¹Thomson Reuters Healthcare, Cambridge, MA, ²Amgen Inc., Thousand Oaks, CA
Background/Purpose: Tumor Necrosis Factor Inhibitors (TNFi) are the mainstay of treatment for rheumatoid arthritis (RA) in patients with moderate to severe disease. The three most…
Abstract Number: 1830 • 2012 ACR/ARHP Annual Meeting
Drugs Are the Major Cost Driver of Rheumatoid Arthritis As Soon As the First Year of the Disease: An Economic Analysis Based On the Espoir Cohort Data
Bruno Fautrel¹, Sandy Lucier², Georges Haour², Hassani Maoulida², Stephanie Harvard¹, Alain Saraux³, Xavier Mariette⁴, Francis Guillemin⁵, Isabelle Durand-Zaleski² and Karine Chevreul², ¹Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, ²APHP - URC Eco, Paris, France, ³Department of rheumatology and unit of immunology (EA 2216), Université Brest Occidentale, Brest, France, ⁴Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France, ⁵Hopitaux de Brabois, Nancy, France
Background/Purpose: Many studies have explored the economic burden of established RA but few data are available about the determinants of costs in early rheumatoid arthritis…
Abstract Number: 1831 • 2012 ACR/ARHP Annual Meeting
Evaluation of the Cost-Effectiveness of Rheumatoid Arthritis Treatment with Biologic Agents Using the IORRA Cohort Database
Eiichi Tanaka¹, Eisuke Inoue², Daisuke Hoshi³, Akiko Kobayashi², Naoki Sugimoto², Kumi Shidara², Eri Sato³, Yasushi Inoue³, Yohei Seto², Ayako Nakajima⁴, Shigeki Momohara³, Atsuo Taniguchi² and Hisashi Yamanaka³, ¹Tokyo Women's Medical University, Tokyo, Japan, ²Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ³Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁴Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: Rheumatoid arthritis (RA), a chronic inflammatory disorder, causes a significant decrease in quality of life. Recently developed biologic agents (BAs) have caused a considerable…
Abstract Number: 1833 • 2012 ACR/ARHP Annual Meeting
Healthcare Costs in Psoriatic Arthritis Patients Newly Initiated On a Biologic Disease-Modifying Anti-Rheumatic Drug or Methotrexate
Frank Zhang¹, Robert Hiscock² and Jeffrey R. Curtis³, ¹Pricing and Market Access, I&I, Celgene Corporation, Warren, NJ, ²Analysis Group, Inc., Montreal, QC, Canada, ³Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Several treatment options are available for psoriatic arthritis (PsA) patients (pts). The healthcare cost associated with the management of PsA pts varies depending on…
Abstract Number: 1812 • 2012 ACR/ARHP Annual Meeting
A Retrospective Evaluation of the Clinical and Economic Implications of Gout in Nursing Home Residents in Hawaii Treated with Allopurinol
Joy Higa¹, Gregory Reardon² and Gregory Tong³, ¹Long Term Care Research Center, Kaneohe, HI, ²Informagenics, LLC, Worthington, OH, ³Takeda Pharmaceuticals America, Inc., Deerfield, IL
Background/Purpose: We describe patient characteristics, serum uric acid (sUA) levels while on allopurinol, and activities of daily living (ADL) in nursing home residents with gout.…
Abstract Number: 1815 • 2012 ACR/ARHP Annual Meeting
Factors Associated with a Prolonged Hospital Length of Stay for Patients with Acute Gout
Rebecca Sharim¹, Meghan Musselman² and Marissa Blum³, ¹Department of Medicine, Temple University Hospital, Philadelphia, PA, ²Temple University School of Medicine, Philadelphia, PA, ³Medicine/Rheumatology, Temple University School of Medicine, Philadelphia, PA
Background/Purpose: Management of gout in the hospital setting has been poor. This study aimed to describe patient characteristics and the treatment patterns of acute gout…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].